Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $13.32 and traded as high as $13.80. Reckitt Benckiser Group shares last traded at $13.80, with a volume of 241,622 shares traded.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Sanford C. Bernstein raised shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Royal Bank Of Canada reissued an "outperform" rating on shares of Reckitt Benckiser Group in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Reckitt Benckiser Group currently has an average rating of "Buy".
Check Out Our Latest Stock Analysis on RBGLY
Reckitt Benckiser Group Trading Down 0.1%
The stock's 50 day moving average price is $13.32 and its 200 day moving average price is $13.00. The company has a quick ratio of 0.39, a current ratio of 0.58 and a debt-to-equity ratio of 1.08.
Reckitt Benckiser Group Company Profile
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
